Scholars Central

Conference abstract

Growth factor independent 1 (Gfi1) as a new target for the therapy of Lymphoid leukemia and lymphoma

Authors: Tarik Moroy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Lymphoma and leukemia have an incidence of approximately 8% in North America and Europe. However, a large proportion of patients cannot be cured despite intensive therapy and new therapeutic approaches are warranted. We found that the transcriptional repressor protein Growth factor independent-1 (Gfi1) is critical for the initiation and progression of lymphoid leukemia and lymphoma and that inhibition or ablation of Gfi1 significantly delayed or completely prevented the initiation of T-cell lymphoma. This was observed using several independent experimental models in which we provoked a T-cell tumor by injecting mice with a carcinogen (N-ethyl-N-nitrosourea (ENU)) or infecting them with a non acute transforming retrovirus (MoMuLV) or where we overexpressed a truncated Notch transgene (NotchΔCT) mimicking Notch mutations of human T-ALL cases. Most striking was that the ablation of Gfi1 in these tumor models led to the cure of mice without use of additional chemotherapy. In addition, we also observed that inhibition of Gfi1 could stop the expansion of leukemic cells from T-ALL patients grafted into immune-deficient mice. Biochemical analyses indicated that Gfi1 exerts its function by restricting the activity of the tumor suppressor p53 by limiting its methylation at K372 and thus its ability to activate pro-apoptotic targets genes such as Bax, Noxa (Pmaip1) and Puma (Bbc3) . Since malignant transformation can induce stress and a DNA damage response, tumors with non- mutated p53 such as many lymphoid leukemias or lymphomas have to select for Gfi1 expression to counteract p53 induced cell death. In this situation, the inhibition or removal of Gfi1 leads to accelerated p53 mediated cell death and to tumor regression. We conclude that lymphoid leukemia are dependent upon Gfi1 and that Gfi1 may be suitable as a new therapeutic target to treat lymphoid malignancies, in particular by complementing the classical radio- and chemotherapy, which induce a DNA damage response in tumor cells.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Blood Disorders & Transfusion.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Tarik Moroy”